AI-generated analysis. Always verify with the original filing.
Tivic Health Systems, Inc. issued a press release reporting full year 2025 financial results, including operating expenses of $7.9 million and loss from discontinued operations of $900,000, with net loss expected at $8.8 million to $9.1 million. The company announced its strategic transformation into an immunotherapy company, acquiring Entolimod rights and establishing Velocity Bioworks CDMO.
Event Type
Disclosure
Mandatory
Variant
8-K
. Item 7.01 Regulation FD Disclosure. On March 25, 2026, Tivic Health Systems, Inc. (the "Company") issued a press release regarding the Company’s financial res
of this Current Report, including Exhibit 99.1 attached hereto, shall not be incorporated by reference into any filing under the Securities Act of 1933, as amen
Financial Statements and Exhibits. (d) Exhibits. Exhibit No. Description 99.1 Press Release, dated March 25, 2026. 104 Cover Page Interactive Data File (formatt
| Metric | Value | Basis |
|---|---|---|
| Operating expenses | $7.90 | |
| Loss from discontinued operations | $0.90 |